Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects.

The pharmacogenomics journal - 1 Jun 2024

Barratt Daniel T, Klepstad Pål, Dale Ola, Kaasa Stein, Somogyi Andrew A

Abstract excerpt

The aim was to determine if opioid neuroimmunopharmacology pathway gene polymorphisms alter serum morphine, morphine-3-glucuronide and morphine-6-glucuronide concentration-response relationships in 506 cancer patients receiving controlled-release oral morphine. Morphine-3-glucuronide concentrations (standardised to 11 h post-dose) were higher in patients without pain control (median (interquartile range) 1.2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Analgesics, Opioid
Share to Delayed-Action Preparations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Morphine

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Share to Polymorphism, Single Nucleotide

Share to Toll-Like Receptor 2

Source

Open in PubMed Open full text

Identifiers

PMID: 38824169
DOI: 10.1038/s41397-024-00339-w
PMCID: PMC11144121

Genes

BDNF
IL2
IL6
IL6R
TLR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects.PMID 38824169Read ↗

Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl.Semantic proximity Read ↗

Pain polymorphisms and opioids: An evidence based reviewSemantic proximity Read ↗

Innate Immune and Neuronal Genetic Markers Are Highly Predictive of Postoperative Pain and Morphine Patient-Controlled Analgesia Requirements in Indian but Not Chinese or Malay Hysterectomy Patients.Semantic proximity Read ↗

Role of genetic polymorphisms on opioid safety and efficacy in cancer pain: A systematic review and meta-analysis.Semantic proximity Read ↗

Opioids for chronic pain: molecular and genomic basis of actions and adverse effects.Semantic proximity Read ↗

Association Between Human Pain-Related Genotypes and Variability in Opioid Analgesia: An Updated Review.Semantic proximity Read ↗

Influence of genetic variants of opioid-related genes on opioid-induced adverse effects in patients with lung cancer: A STROBE-compliant observational study.Semantic proximity Read ↗

Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain.Semantic proximity Read ↗

Clinical trials of cancer-related pain : translational research linking genetic variation to pain experience and response to oral opioidsSemantic proximity Read ↗

Optimising opioids for cancer pain : investigating the basis of inter-individual analgesic response and side-effect profileSemantic proximity Read ↗

Cancer Pain is Not One Size Fits All: Evolving from Tradition to PrecisionSemantic proximity Read ↗

Oxycodone/naloxone versus Tapentadol in real-world chronic non-cancer pain management: a prospective controlled and pharmacogenetic studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.